DxS Enters Into Collaboration With Bristol-Myers Squibb And ImClone Systems To Provide a K-RAS Companion Diagnostic For ERBITUX

04-Sep-2009 - DxS has entered into a collaboration agreement with Bristol-Myers Squibb Company and ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, to further develop a K-RAS companion diagnostic for ERBITUX® (cetuximab) in the United States and Canada. If approved by the U.S. Food and ...

Lilly Completes Cash Tender Offer for ImClone Systems

26-Nov-2008 - Eli Lilly and Company and ImClone Systems Incorporated announced the successful completion of the previously announced tender offer by Lilly's wholly-owned subsidiary, Alaska Acquisition Corporation, for all outstanding shares of ImClone at a price of $70.00 per share in cash. The offer expired ...

Dyax Corp. Announces Extension of Antibody Library Collaboration with ImClone Systems

12-Nov-2007 - Dyax Corp. announced the extension of the antibody library collaboration with ImClone Systems Incorporated for the discovery of therapeutic antibodies. Under the terms of this agreement, ImClone will continue to have access to Dyax's proprietary phage display technology for an additional four ...

Merck Announces Joint Agreement With ImClone and Bristol-Myers Squibb for Erbitux in Japan

Co-development and co-commercialization of Erbitux in metastatic colorectal cancer upon health authority approval

19-Oct-2007 - Merck KGaA announced that it has established an agreement with ImClone Systems Incorporated and Bristol-Myers Squibb Company for the co-development and co-commercialization of Erbitux® (cetuximab) in Japan if approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA). Under ...

UCB gains global rights pertaining to VEGFR-2 for CDP-791

08-Feb-2007 - UCB announced that UCB and ImClone Systems Incorporated have agreed to terminate their CDP-791 development agreement. UCB will enjoy freedom to operate rights globally to ImClone's intellectual property pertaining to vascular endothelial growth factor receptor-2 ("VEGFR-2") for CDP-791. In ...

UCB and Imclone Systems enter into worldwide partnership for CDP-791 therapy targeting the development of tumor vasculature

18-Aug-2005 - UCB and ImClone Systems Incorporated announced that they have entered into a worldwide strategic partnership for the development and commercialization of CDP-791, a novel, investigational antibody targeting the vascular endothelial growth factor receptor-2 (VEGFR-2) that is currently being ...